BLPH Bellerophon Therapeutics, Inc.

1.08
+0.17  (18.67%)
Previous Close 0.91
Open 0.90
Price To book 0.73
Market Cap 15.67M
Shares 14,506,000
Volume 2,187,701
Short Ratio 1.15
Av. Daily Volume 867,856

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 initiated May 2016. Data due 1Q 2017.
INOpulse delivery device
Pulmonary Hypertension associated with Idiopathic Pulmonary Fibrosis (PH-IPF)
Phase 3 commenced enrolment June 2016. Interim data due 4Q 2017 with top-line data due mid-2018.
INOpulse delivery device
Pulmonary Arterial Hypertension (PAH)
Phase 2 initiated 3Q 2016. Data due 1Q 2017.
INOpulse delivery device
Pulmonary Hypertension associated with COPD (PH-COPD)

Latest News

  1. Coverage initiated on Bellerophon Therapeutics by H.C. Wainwright
  2. BELLEROPHON THERAPEUTICS, INC. Files SEC form 8-K, Notice of Delisting or Failure to Satisfy a Continued Listing Rule
  3. BELLEROPHON THERAPEUTICS, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits
  4. Bellerophon Therapeutics Announces FDA Acceptance of Modifications to INOpulse Pulmonary Arterial Hypertension Phase 3 Program
  5. Bellerophon Therapeutics Announces FDA Acceptance of Modifications to INOpulse Pulmonary Arterial Hypertension Phase 3 Program
  6. These 5 Stocks Under $10 Could Make You a Lot of Money
  7. BELLEROPHON THERAPEUTICS, INC. Files SEC form 8-K, Change in Directors or Principal Officers
  8. BELLEROPHON THERAPEUTICS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements a
  9. Bellerophon Therapeutics, Inc. Announces $12 Million Public Offering
  10. Bellerophon Therapeutics, Inc. Announces $12 Million Public Offering
  11. BELLEROPHON THERAPEUTICS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Change in Directors or
  12. BELLEROPHON THERAPEUTICS, INC. Financials
  13. Bellerophon Reports Third Quarter 2016 Financial Results and Provides Business Update
  14. BELLEROPHON THERAPEUTICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statement
  15. BELLEROPHON THERAPEUTICS, INC. Files SEC form 10-Q, Quarterly Report
  16. INVESTOR ALERT: Goldberg Law PC Announces an Investigation of Bellerophon Therapeutics, Inc. and Advises Investors with Losses to Contact the Firm
  17. Robbins Arroyo LLP is Investigating the Officers and Directors of Bellerophon Therapeutics, Inc. (BLPH) on Behalf of Shareholders
  18. SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Bellerophon Therapeutics, Inc. (BLPH)
  19. Second Law Firm Hits Bellerophon (BLPH)
  20. INVESTOR ALERT: Investigation of Bellerophon Therapeutics, Inc. Announced by Law Offices of Howard G. Smith